未登录.png)
分享.png)
收藏分享 收藏 分享 收藏 A prospective cohort study of abemaciclib-induced interstitial lung disease in metastatic breast cancer after chemotherapy
Nakayama, Sayuka; Iwamoto, Takayuki; Araki, Kazuhiro; Narui, Kazutaka; Nakayama, Takahiro; Nagase, Hiroyuki; Sugimoto, Naoya; Taira, Naruto; Aihara, Tomohiko; Kikawa, Yuichiro; Mukai, Hirofumi 分享 收藏 Real-world incidence of and risk factors for abemaciclib-induced interstitial lung disease in Japan: a nested case-control study of abemaciclib-induced interstitial lung disease (NOSIDE)Nakayama, Sayuka; Yoshizawa, Ayuha; Tsurutani, Junji; Yoshimura, Kenichi; Aoki, Gaku; Iwamoto, Takayuki; Nagase, Hiroyuki; Sugimoto, Naoya; Kobayashi, Konomi; Izumi, Shinyu; Kato, Terufumi; Miyazaki, Yasunari; Kurihara, Yasuyuki; Taira, Naruto; Aihara, Tomohiko; Kikawa, Yuichiro; Mukai, Hirofumi 分享 收藏 A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancerNoguchi, Emi; Yamanaka, Takashi; Mukai, Hirofumi; Yamamoto, Naohito; Chung, Chi-Feng; Lu, Yen-Shen; Chang, Dwan-Ying; Sohn, Joohyuk; Kim, Gun Min; Lee, Kyung-Hun; Lee, Soo-Chin; Iwasa, Tsutomu; Iwata, Hiroji; Watanabe, Kenichi; Jung, Kyung Hae; Tanabe, Yuko; Kang, Seok Yun; Yasojima, Hiroyuki; Aogi, Kenjiro; Tokunaga, Eriko; Sim, Sung Hoon; Yap, Yoon Sim; Matsumoto, Koji; Tseng, Ling-Ming; Umeyama, Yoshiko; Sudo, Kazuki; Kojima, Yuki; Hata, Tomomi; Kuchiba, Aya; Shibata, Taro; Nakamura, Kenichi; Fujiwara, Yasuhiro; Tamura, Kenji; Yonemori, Kan 分享 收藏 Eribulin versus S-1 as fi rst or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a noninferiority, randomised, controlled, open-label, phase 3 trialTakahashi, Masato; Kikawa, Yuichiro; Kashiwabara, Kosuke; Taira, Naruto; Iwatani, Tsuguo; Shimozuma, Kojiro; Ohtani, Shoichiro; Yoshinami, Tetsuhiro; Watanabe, Junichiro; Kashiwaba, Masahiro; Watanabe, Ken-ichi; Kitada, Masahiro; Sakaguchi, Koichi; Tanabe, Yuko; Aihara, Tomohiko; Mukai, Hirofumi 分享 收藏 Comparison of proportions and prognostic impact of pathological complete response between evaluations of representative specimen and total specimen in primary breast cancer after neoadjuvant chemoradiotherapy: an ancillary study of JCOG0306Shien, Tadahiko; Tsuda, Hitoshi; Sasaki, Keita; Mizusawa, Junki; Akiyama, Futoshi; Kurosumi, Masafumi; Sawaki, Masataka; Tamura, Nobuko; Tanaka, Kiyo; Kogawa, Takahiro; Takahashi, Mina; Hayashi, Naoki; Mukai, Hirofumi; Masuda, Norikazu; Hara, Fumikata; Iwata, Hiroji 分享 收藏 Clonal Architecture of circulating tumor DNA predicts Early Progression on Tamoxifen With or Without Palbociclib in Hormone Receptor-Positive Advanced Breast Cancer: NCCH1607/PATHWAY trialYap, Yoon-Sim; Kojima, Yuki; Hamada, Akinobu; Mukai, Hirofumi; Lu, Yen-Shen; Sohn, Joo Hyuk; Umeyama, Yoshiko; Noguchi, Emi; Sudo, Kazuki; Hata, Tomomi; Kuchiba, Aya; Shibata, Taro; Yagishita, Shigehiro; Yoshida, Masayuki; Kohsaka, Shinji; Shiraishi, Kouya; Nakamura, Kenichi; Tamura, Kenji; Yonemori, Kan 分享 收藏 分享 收藏 A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancerTakada, Masahiro; Imoto, Shigeru; Ishida, Takanori; Ito, Yoshinori; Iwata, Hiroji; Masuda, Norikazu; Mukai, Hirofumi; Saji, Shigehira; Ikeda, Takafumi; Haga, Hironori; Saeki, Toshiaki; Aogi, Kenjiro; Sugie, Tomoharu; Ueno, Takayuki; Ohno, Shinji; Ishiguro, Hiroshi; Kanbayashi, Chizuko; Miyamoto, Takeshi; Hagiwara, Yasuhiro; Toi, Masakazu 分享 收藏 HSD17B4 methylation enhances glucose dependence of BT-474 breast cancer cells and increases lapatinib sensitivityArai, Nobuaki; Hattori, Naoko; Yamashita, Satoshi; Liu, Yu-Yu; Ebata, Takahiro; Takeuchi, Chihiro; Takeshima, Hideyuki; Fujii, Satoshi; Kondo, Haruhiko; Mukai, Hirofumi; Ushijima, Toshikazu 分享 收藏 Venous thromboembolism in Japanese patients with breast cancer: subgroup analysis of the Cancer-VTE Registry日本乳腺癌患者的静脉血栓栓塞: 癌症-VTE注册的亚组分析Ohsumi, Shozo; Watanabe, Kenichi; Kondo, Naoto; Kosaka, Yoshimasa; Ishikawa, Takashi; Kitahara, Miyuki; Kubo, Shinichiro; Oba, Mari S.; Kimura, Tetsuya; Takita, Atsushi; Mukai, Hirofumi 分享 收藏 Eribulin versus S1 as first- or second-line chemotherapy to assess Health-related Quality of Life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomized controlled trialKikawa, Yuichiro; Kashiwabara, Kosuke; Taira, Naruto; Iwatani, Tsuguo; Shimozuma, Kojiro; Ohtani, Shoichiro; Yoshinami, Tetsuhiro; Watanabe, Junichiro; Kashiwaba, Masahiro; Watanabe, Ken-ichi; Kitada, Masahiro; Sakaguchi, Koichi; Tanabe, Yuko; Aihara, Tomohiko; Mukai, Hirofumi; Takahashi, Masato 分享 收藏 Adjuvant S-1 plus endocrine therapy for estrogen receptor-positive, HER2-negative, primary breast cancer: updated overall survival analysis from the POTENT trialTakada, Masahiro; Saji, Shigehira; Ueno, Takayuki; Masuda, Norikazu; Ishiguro, Hiroshi; Ishida, Takanori; Saeki, Toshiaki; Imoto, Shigeru; Ohno, Shinji; Iwata, Hiroji; Sugie, Tomoharu; Aogi, Kenjiro; Mukai, Hirofumi; Takayama, Shin; Sato, Nobuaki; Kai, Yuichiro; Kitada, Masahiro; Nakamura, Rikiya; Matsuyama, Yutaka; Toi, Masakazu 分享 收藏 Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort studySawaki, Masataka; Taira, Naruto; Uemura, Yukari; Saito, Tsuyoshi; Baba, Shinichi; Kobayashi, Kokoro; Kawashima, Hiroaki; Tsuneizumi, Michiko; Sagawa, Noriko; Bando, Hiroko; Takahashi, Masato; Yamaguchi, Miki; Takashima, Tsutomu; Nakayama, Takahiro; Kashiwaba, Masahiro; Mizuno, Toshiro; Yamamoto, Yutaka; Iwata, Hiroji; Toyama, Tatsuya; Tsugawa, Koichiro; Kawahara, Takuya; Mukai, Hirofumi 分享 收藏 Efficacy of Telemedicine Using Videoconferencing Systems in Outpatient Care for Patients With Cancer: A Systematic Review and Meta-AnalysisUemoto, Yasuaki; Yamanaka, Taro; Kataoka, Yuki; Wada, Yoshitaka; Aoyama, Yosuke; Kizawa, Rika; Yamaguchi, Takeshi; Kikawa, Yuichiro; Mukai, Hirofumi; Taira, Naruto 分享 收藏 Neoadjuvant pembrolizumab/placebo plus chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroupTakahashi, Masato; Cortes, Javier; Dent, Rebecca; Pusztai, Lajos; Mcarthur, Heather; Kuemmel, Sherko; Denkert, Carsten; Park, Yeon Hee; Im, Seock-Ah; Ahn, Jin-Hee; Mukai, Hirofumi; Huang, Chiun-Sheng; Chen, Shin-Cheh; Kim, Min Hwan; Jia, Liyi; Li, Xin Tong; Tryfonidis, Konstantinos; Karantza, Vassiliki; Iwata, Hiroji; Schmid, Peter 分享 收藏 One-year incidence of venous thromboembolism, bleeding, and death in patients with solid tumors newly initiating cancer treatment: Results from the Cancer-VTE RegistryOhashi, Yasuo; Ikeda, Masataka; Kunitoh, Hideo; Sasako, Mitsuru; Okusaka, Takuji; Mukai, Hirofumi; Fujiwara, Keiichi; Nakamura, Mashio; Oba, Mari S.; Kimura, Tetsuya; Ibusuki, Kei; Takita, Atsushi; Sakon, Masato 分享 收藏 Randomized study comparing electronic patient reported outcomes (ePROs) monitoring with routine follow up during trastuzumab deruxtecan treatment in patients with inoperable or metastatic breast cancer (PRO-DUCE study)Sangai, Takafumi; Kikawa, Yuichiro; Hosoda, Mitsuchika; Hamanaka, Yohei; Tanabe, Yuko; Yoshida, Tatsuya; Tane, Kaori; Takabatake, Daisuke; Taira, Tetsuhiko; Araki, Kazuhiro; Iwamoto, Takayuki; Takada, Mamoru; Narui, Kazutaka; Yamaguchi, Takeshi; Yamada, Akimitsu; Miura, Tomoko; Uemura, Yukari; Aihara, Tomohiko; Mukai, Hirofumi; Taira, Naruto 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
